Life-science briefing: Thursday, March 6, 2008
TODAY’S HEADLINES:
France’s TxCell raises €11M for cell therapy (release)
Healthcare IT firm TriHealix takes in $7M (release)
Healthcare-software provider Anodyne Health acquires Piedmont Healthcare (release)
CEO, CFO resign at inhaled-drug biotech Topigen (release)
France’s TxCell raises €11M for cell therapy – TxCell, a French cell-therapy biotech, raised €10.5 million ($16 million) in a second funding round. Investors included Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure.
The biotech is developing a patient-specific cell therapy for the gastrointestinal autoimmune… Continue Reading
Three yards and a cloud of dust: Bioheart limps across the IPO goal line, but with little to show for its struggles
The New York Giants they ain’t, but the team at embattled cell-therapy startup Bioheart still managed to defy long odds and successfully dragged their company into the IPO endzone earlier today. No doubt football great Dan Marino — one of the Sunrise, Fla., biotech’s backers — fired everyone up with a suitable locker-room pep talk.
Not for Bioheart was the easy dodge of yanking its IPO due to “unfavorable market conditions” — although conditions are, in… Continue Reading